Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SR31747A · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| SR31747A | DRUG | - |
Inclusion Criteria: * Prior confirmed histological diagnosis of prostatic carcinoma. * Rising PSA while receiving hormonal therapy or after surgical castration defined as 2 sequential increases above a previous lowest reference value within the past 12 months; PSA must be at least 4ng/ml at the tim...
SR31747A is an investigational small molecule being studied for the treatment of prostatic neoplasm, specifically in patients with androgen-independent non-metastatic prostate cancer. It is being developed by Sanofi and has been evaluated in a Phase 2 clinical trial.
SR31747A is being developed by Sanofi, a biopharmaceutical company listed on the stock exchange under the ticker SNY. The drug is an investigational small molecule in the oncology therapeutic area.
SR31747A is in Phase 2 clinical development. It has completed a Phase 2 trial, and the drug remains investigational, meaning it has not been approved by regulatory authorities. Its development status is based on the completed trial data.
SR31747A has been studied in one completed Phase 2 clinical trial, identified as NCT00174863. This trial evaluated SR 31747A versus placebo in androgen-independent non-metastatic prostate cancer and enrolled 232 participants across multiple countries.
Yes, SR31747A and SR 31747A refer to the same drug. The clinical trial record for the drug uses the name SR 31747A, while the drug is also referred to as SR31747A. Both names denote the same investigational small molecule.